Equities Analysts Offer Predictions for Gilead Sciences, Inc.’s Q1 2018 Earnings (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) – Analysts at Leerink Swann lowered their Q1 2018 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on Wednesday. Leerink Swann analyst G. Porges now expects that the biopharmaceutical company will earn $1.68 per share for the quarter, down from their previous estimate of $1.79. Leerink Swann currently has a “Market Perform” rating and a $83.00 target price on the stock. Leerink Swann also issued estimates for Gilead Sciences’ Q2 2018 earnings at $1.61 EPS and Q3 2018 earnings at $1.57 EPS.
A number of other research firms also recently commented on GILD. Vetr downgraded Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 price objective on the stock. in a report on Monday, January 29th. Citigroup upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price objective for the stock from $88.80 to $76.00 in a report on Tuesday, January 30th. Bank of America increased their price objective on Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a report on Wednesday, February 7th. Morgan Stanley dropped their price objective on Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 7th. Finally, BMO Capital Markets increased their price objective on Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a report on Thursday, February 8th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $87.04.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter in the prior year, the company posted $2.70 earnings per share. The firm’s revenue was down 18.7% on a year-over-year basis.
Hedge funds and other institutional investors have recently modified their holdings of the business. Welch Investments LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at $108,000. Wealthcare Advisory Partners LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at $133,000. Horan Capital Advisors LLC. acquired a new stake in shares of Gilead Sciences in the third quarter valued at $144,000. Hanson & Doremus Investment Management increased its stake in shares of Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Gilead Sciences in the second quarter valued at $147,000. 76.47% of the stock is owned by institutional investors.
In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $73.87, for a total transaction of $1,108,050.00. Following the completion of the transaction, the executive vice president now directly owns 64,613 shares of the company’s stock, valued at $4,772,962.31. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the transaction, the insider now directly owns 3,046,766 shares of the company’s stock, valued at $224,302,912.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 418,333 shares of company stock valued at $32,742,108. 1.30% of the stock is owned by company insiders.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be given a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 2.82%. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is 59.77%.
ILLEGAL ACTIVITY NOTICE: “Equities Analysts Offer Predictions for Gilead Sciences, Inc.’s Q1 2018 Earnings (GILD)” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://theolympiareport.com/2018/02/14/equities-analysts-offer-predictions-for-gilead-sciences-inc-s-q1-2018-earnings-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.